



ELISA-VIDITEST anti-HHV-6 IgG

ODZ-235

Instruction manual

PRODUCER: VIDIA spol.s r.o., Nad Safinou II 365, 252 50 Vestec, Czech Republic, Tel.: +420 261 090 565, Fax: +420 261 090 566, www.vidia.cz

1. TITLE

ELISA-VIDITEST anti-HHV-6 IgG – ELISA kit for detection of IgG antibodies to HHV-6 in human serum samples.

2. INTENDED USE

The kits is intended for serological diagnosis of diseases associated with HHV–6 infection, such as exanthema subitum, acute respiratory illnesses, diarrhoea with fever and febrile seizures in infants, heterophile antibody-negative infectious mononucleosis in children, also interstitial pneumonia, encephalitis, meningitis, hepatitis and aplastic anemia in immunodeficient patients. The presence of IgG anti-HHV-6 antibody reveals the immune status of the patient. Significant rise in anti-HHV-6 IgG antibodies in paired serum samples, taken in acute and convalescent phase of the infection, is indicative of the active infection. The test does not differentiate between HHV-6 subtype A and B.

3. TEST PRINCIPLE

ELISA-VIDITEST anti-HHV-6 IgG assay is a solid-phase immunoanalytical test. The strips are coated with native HHV-6 antigen. The anti-HHV-6 antibodies, if present in the sera tested, bind to the immobilized antigens and the antibodies being in complexes with antigen are later on recognised by animal anti-human IgG antibodies labelled with horseradish peroxidase. The attached labelled antibodies are revealed by an enzymatic reaction with a chromogenic substrate. Negative sera do not react - a mild change in colour, if present, may be attributed to the reaction background.

4. KIT COMPONENTS

ELISA strips coated with native antigen	STRIPS	Ag	1 microplate
1.3 mL Standard A=negative control serum, r.t.u. ¹⁾	STA/NC		1 vial
1.3 mL Standard D= calibrator, r.t.u.	STD/CAL		1 vial
1.3 mL Standard E= positive control serum, r.t.u.	STE/PC		1 vial
13 mL Anti-human IgG antibodies labelled with horseradish with horseradish peroxidase (Px-conjugate) r.t.u.	CONJ		1 vial
55 mL Wash buffer 10x concentrated	WASH	10x	1 vial
60 mL Dilution buffer anti-HHV6 r.t.u.	DIL		1 vial
13 mL Chromogenic substrate (TMB-O substrate) r.t.u.	TMB-O		1 vial
13 mL Stop solution r.t.u.	STOP		1 vial

Instruction manual

Certificate of quality

¹⁾ ready to use

Notice: Control sera may be colorless to yellowish or blue due to the use of different diluents.

Dilution Buffer [DIL] is intended only for ELISA-VIDITEST anti-HHV-6 IgG, IgM kits. Chromogenic substrate [TMB-O] is compatible and interchangeable between ELISA-VIDITEST kits which contain [TMB-O] and not with other Chromogenic substrates [TMB], [TMB-BF].

5. MATERIAL REQUIRED BUT NOT PROVIDED WITH THE KIT

1. Distilled or deionised water for dilution of the Wash buffer concentrate.
2. Appropriate equipment for pipetting, liquid dispensing and washing.
3. Spectrophotometer/colorimeter (microplate reader – wavelength 450 nm).

6. PREPARATION OF REAGENTS AND SAMPLES

- a. **Allow all kit components to reach room temperature.**
- b. **Mix samples, Standards and the Negative control in order to ensure homogeneity** and mix all solution well prior use.
- c. **Dilute serum samples 1:100 in Dilution buffer** and mix (5 µL of serum sample + 500 µL of Dilution buffer). **Do not dilute Controls** (Standards), Px-conjugate, TMB-O substrate and Stop solution, they are ready to use.
- d. Prepare Wash buffer by diluting the Wash buffer concentrate 10 times with an appropriate volume of distilled or deionised water (e.g. 50 mL of the concentrated Wash buffer + 450 mL of distilled water). If there are crystals of salt present in the concentrated Wash buffer, warm up the vial to +32 to +37°C in a water bath. Diluted Wash buffer is stable for one month at room temperature.
- e. **Do not dilute** Px-conjugate, TMB-O substrate and Stop solution, they are ready to use (r.t.u.).

7. ASSAY PROCEDURE

Manufacturer will not be held responsible for results if manual is not followed exactly.

- a. Allow the vacuum-closed aluminium bag with strips to reach a room temperature. Withdraw the adequate number of strips and put unused strips into the provided pouch and seal it carefully with the desiccant kept inside.
- b. Pipette 100 µL of Dilution buffer, Standards, Negative control and serum samples to the wells according to the pipetting scheme in Figure 1: start with filling the first well dilution buffer [DIL], the next two wells with Standard D [ST D/CAL], next well with Positive control serum [ST E/PC] and another one well with Negative control serum [ST A/NC]. Standard D serves as a calibrator. Fill the remaining wells with diluted serum samples (S1, S2, S3...). It is satisfactory to apply samples and controls as singlets, however, if you want to minimize laboratory error then apply the [STD/CAL] in triplet, controls and samples in doublets.
- c. Incubate **60 minutes (±5 min)** at room temperature.
- d. Aspirate the liquid from the wells into a collecting bottle containing appropriate disinfectant (see Safety Precautions). Wash and aspirate the wells four times with 250 µl/well of Wash buffer. Avoid cross-contamination between wells!
If some liquid remains in the wells, invert the plate and tap it on an adsorbent paper to remove the last remaining drops.
- e. Add 100 µL of Px-conjugate r.t.u. [CONJ] into each well.
- f. **Incubate 60 minutes (±5 min) at room temperature.**
- g. Aspirate and wash four times with 250 µl/well of Wash buffer.
- h. Dispense 100 µl of [TMB-O] substrate into each well.
- i. Incubate for **20 minutes (+/-30 seconds)** at room temperature.

The time measurement must be started at the beginning of TMB-O dispensing.

Cover the strips with an aluminium foil or keep them in the dark during the incubation with TMB-O substrate.

- j. Stop the reaction by adding 100 µL of Stop solution **STOP**. Use the same pipetting rhythm as with the TMB-O substrate to ensure the same reaction time in all wells. Tap gently the microplate for a few times to ensure complete mixing of the reagents.
- k. Read the absorbance at **450 nm with a microplate reader within 20 minutes**. It is recommended to use reference reading at 620-690 nm.

Fig 1: Pipetting scheme

	1	2	3	4	5	6	7	8	9	10	11	12
a	DIL	S4										
b	ST D/CAL	S...										
c	ST D/CAL											
d	ST E/PC											
e	ST A/NC											
f	S1											
g	S2											
h	S3											

8. PROCESSING OF THE RESULTS

Begin the processing with subtraction of the absorbance of the DIL well (background absorbance) from the absorbances in all other wells.

If the absorbance of controls or tested sera are negative after background subtraction, consider them as zero value.

8.1 Qualitative evaluation

1. Compute the mean absorbance of the two parallels of Standard D **ST D/CAL**. (If the Standard D was applied in three parallels and one the absorbance is different from the mean more than 20%, then exclude the deviating well from the calculation and compute a new absorbance mean using the other two wells).
2. Compute the cut-off value by multiplying the Standard D mean with a Correction factor. **The Correction factor of Standard D is indicated on Quality Control Certificate.**
3. Assign the samples with absorbances less than the 90 % of the cut-off value as negative and the samples with absorbances higher than 110% of the cut-off value as positive.

8.2 Semiquantitative evaluation

Determination of sample Positivity Index:

1. Compute the cut-off value (see previous paragraph 8.1)
2. Compute the Positivity Index for each sample according to the following formula:

$$\text{Sample Positivity Index} = \frac{\text{sample absorbance}}{\text{cut-off value}}$$

3. Express serum reactivity in accordance with data in Table 1 (Evaluation of results)

Table 1 Evaluation of results

<u>Index value</u>	<u>Interpretation</u>
< 0.90	Negative
0.90 - 1.10	+/-
> 1.10	Positive*

* on the basis of the Positivity Index value it is possible to estimate semiquantitatively the amount of antibodies in the sample

Note! Indifferent sample reactivity, i.e. interpreted as +/-, requires repetition of the sample testing. If the result is repetitively indifferent then it is recommended to use an alternative testing method or to obtain another sample from the patient withdrawn 1-2 weeks later.

Example of calculation:

Standard D absorbances	= 1.407; 1.377
Standard D mean	= 1.392
Correction factor	= 0.21
Cut-off value	= 1.392*0.21 = 0,292
Sample absorbance	= 1.200
Sample Positivity Index	= 1.200 / 0.292 = 4.11

9. RESULTS INTERPRETATION

Anti-HHV-6 IgG antibodies are anamnestic. They persist for the whole life after the primary infection. The kit can detect cross-reactive antibodies to HHV-7. Significant increase of IgG antibodies can be caused by reactivation of the infection, but could not be always proved due to the recurrent character of the reactivations. For final diagnosis, the clinical symptoms of the patient should be taken in consideration. Results from immunosuppressed patients should be interpreted with caution.

10. VALIDITY, SPECIFICITY AND SENSITIVITY OF THE TEST

10.1 Validity of the test

The test is valid if:

The background absorbance (the absorbance of the Dilution buffer) is less than 0.150.

The mean absorbance values of standards/ control sera, and the ratio between the absorbance values of $\frac{ST\ E/PC}{ST\ D/CAL}$ are in the ranges stated in the **Quality control certificate** for this kit lot.

10.2 Precision of the test

The intra-assay and the inter-assay reproducibility were determined using samples with different absorbance values. In anti-HHV-6 IgG-positive samples intra-assay and inter-assay variability coefficients (CV) did not exceed 8% and 15% of mean absorbance values, respectively.

An example of **intra-assay** variability (n= number of parallel determinations in the same test)

n	A	$\pm\sigma$	CV
14	1.536	0.036	2.3 %
16	1.891	0.042	2.2 %

An example of **inter-assay** variability (n= number of determinations in several independent tests)

n	A	$\pm\sigma$	Min.- max.	CV
5	1.601	0.145	1.425-1.747	9.1 %
5	1.162	0.075	1.086-1.238	6.5 %

10.3 Sensitivity and specificity of the test

The diagnostic sensitivity of the test is 99% and the specificity is 95%. Evaluation was performed by the comparing the ELISA-VIDITEST anti-HHV-6 kit with other commercial ELISA tests.

HHV-6 status	Negative	Equivocal	Positive	Sum
Seronegative	40	1	2	43
Seropositive	3	0	245	248

10.4 Accuracy of the test

10.4.1 Spiking recovery test

Measured values of recovery test for every Lot are between 80-120% of expected values.

10.4.2 Interference

Haemolytic and lipemic samples have no influence on the test results up to concentration of 50 mg/mL of haemoglobin, 5 mg/mL of bilirubin and 50 mg/mL of triglycerides. However, examination of such samples is not recommended.

11. SAFETY PRECAUTIONS

All ingredients of the kit are intended for laboratory use only.

Controls contain human sera that has been tested negative for HBsAg, anti-HIV-1,2 and anti-HCV. However they should be regarded as contagious and handled and disposed of according to the appropriate regulations.

Autoclave all reusable materials that were in contact with human samples for 0.5 hour at 121°C, burn disposable ignitable materials, decontaminate liquid wastes and nonignitable materials with 3% chloramine. Liquid wastes containing acid (Stop solution) should be neutralized in 4% sodium bicarbonate solution.

Handle Stop solution with care. Avoid contact with skin or mucous membranes. In case of contact with skin, rinse immediately with plenty of water and seek medical advice.

Do not smoke, eat or drink during work. Do not pipette by mouth. Wear disposable gloves while handling reagents or samples and wash your hands thoroughly afterwards. Avoid spilling or producing aerosol.

12. HANDLING PRECAUTIONS

Manufacturer guarantees performance of the entire ELISA kit. **Dilution Buffer (DIL) and Chromogenic substrate (TMB-O substrate) are intended only for ELISA-VIDITEST anti-HHV-6 IgG kit and THEY ARE NOT COMPATIBLE with other ELISA-VIDITEST kits produced by VIDIA s r.o..**

Follow the assay procedure indicated in the Instruction manual.

Controls (Standards), Dilution buffer, Chromogenic substrate and Px-conjugate contain preservative ProClin 300®.

Avoid microbial contamination of serum samples and kit reagents.

Avoid cross-contamination of reagents.

Avoid contact of the TMB-O substrate with oxidizing agents or metal surfaces.

Variations in the test results are usually due to:

- * Insufficient mixing of reagents and samples
- * Inaccurate pipetting and inadequate incubation times
- * Poor washing technique or spilling the rim of well with sample or Px-conjugate
- * Use of identical pipette tip for different solutions

13. STORAGE AND EXPIRATION

The ELISA kit should be used within three months after opening.

Store the kit and the kit reagents at +2 to +10°C, in a dry place and protected from the light. Store unused strips in the sealable pouch and keep the desiccant inside. Store serum samples at +2 to +10°C up to one week. For longer period make aliquots and keep them at -20°C. Avoid repeated thawing and freezing. Do not store diluted samples. Always prepare fresh.

Kits are shipped in cooling bags, the transport time of 72 hours have no influence on expiration. If you find damage at any part of the kit, please inform the manufacturer immediately.

Expiration date is indicated at the ELISA kit label and at all reagent labels.

14. USED SYMBOLS



number of tests



Conformité Européenne – product meets the requirements of European legislation



in vitro diagnostics

$\pm\sigma$

standard deviation

CV

coefficient of variation

OD

optical density




manufacturer



expiration



Lot of kit



storage at +2°C - +10°C

°C

Celsius degree

%

percentage

n

number of tested samples

A

value of tested sample



read usage instructions


Cat. No. catalog number

References:

Salahuddin S.Z., Ablashi D.V., Markham P.D., Joseph S.F., Sturzenegger S., Kaplan M. Halligan G., Biberfeld P., Wong-Stall F., Kramarsky B., Gallo R.C.; Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. *Science* 234: 596-601, 1986

De Bolle L., Naesens L., De Clercq E., Update on Human Herpesvirus 6 Biology, Clinical Features and Therapy, *Clinical Microbiology Reviews*, 217-245, 2005

15. FLOW CHART



Date of the last revision of this manual: 03/2018

The development of this kit was supported by grant from the Ministry of Industry and Trade of the Czech Republic.

